177 related articles for article (PubMed ID: 36777502)
1. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis.
Di Cristofano FR; Fong MW; Huntington KE; Carneiro BA; Zhou L; El-Deiry WS
Am J Cancer Res; 2023; 13(1):307-325. PubMed ID: 36777502
[TBL] [Abstract][Full Text] [Related]
2. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
3. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
[TBL] [Abstract][Full Text] [Related]
4. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Okumura K; Huang S; Sinicrope FA
Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
[TBL] [Abstract][Full Text] [Related]
6. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
7. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
8. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
[TBL] [Abstract][Full Text] [Related]
9. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
[TBL] [Abstract][Full Text] [Related]
10. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Talekar MK; Allen JE; Dicker DT; El-Deiry WS
Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
[TBL] [Abstract][Full Text] [Related]
11. The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA.
Weller S; Toennießen A; Schaefer B; Beigl T; Muenchow A; Böpple K; Hofmann U; Gillissen BF; Aulitzky WE; Kopp HG; Essmann F
Cell Death Discov; 2022 Apr; 8(1):215. PubMed ID: 35443750
[TBL] [Abstract][Full Text] [Related]
12. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Wei X; Zhou P; Lin X; Lin Y; Wu S; Diao P; Xie H; Xie K; Tang P
Tumour Biol; 2014 Oct; 35(10):10213-21. PubMed ID: 25027405
[TBL] [Abstract][Full Text] [Related]
13. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
16. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
17. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
18. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
Zhang Y; Tapinos N; Lulla R; El-Deiry WS
Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
[TBL] [Abstract][Full Text] [Related]
19. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
Song JH; Kandasamy K; Kraft AS
J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
[TBL] [Abstract][Full Text] [Related]
20. The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.
Sundaramoorthy P; Gasparetto C; Kang Y
Cancer Med; 2018 Jul; 7(7):3257-3268. PubMed ID: 29761903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]